These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6619048)

  • 41. Temocillin treatment of gynaecological infections with special reference to blood and tissue concentrations.
    Weissenbacher ER; Gutschow K; Bauernfeind A; Luehr HG
    Drugs; 1985; 29 Suppl 5():178-81. PubMed ID: 3896737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human pharmacokinetics of temocillin (BRL 17421) side chain epimers.
    Guest EA; Horton R; Mellows G; Slocombe B; Swaisland AJ; Tasker TC
    J Antimicrob Chemother; 1985 Mar; 15(3):327-36. PubMed ID: 3997707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis.
    Stass H; Rink AD; Delesen H; Kubitza D; Vestweber KH
    J Antimicrob Chemother; 2006 Sep; 58(3):693-6. PubMed ID: 16895940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renal clearance of temocillin in volunteers.
    Overbosch D; van Gulpen C; Mattie H
    Drugs; 1985; 29 Suppl 5():128-34. PubMed ID: 4029016
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Penetration and exposure of cefotiam into the peritoneal fluid of abdominal surgery patients after intravenous administration.
    Ikawa K; Morikawa N; Fukuhara K; Hayato S; Ikeda K; Soga Y; Ohge H; Sueda T
    J Chemother; 2008 Jun; 20(3):319-23. PubMed ID: 18606586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
    Soubirou JF; Rossi B; Couffignal C; Ruppé E; Chau F; Massias L; Lepeule R; Mentre F; Fantin B
    J Antimicrob Chemother; 2015 May; 70(5):1466-72. PubMed ID: 25564564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacokinetic studies of piperacillin after 4 g or 8 g intravenous injection in human healthy volunteers].
    Nakagawa K; Yasuda T; Nakajima Y; Watanabe Y; Noguchi M; Suzuki T
    Jpn J Antibiot; 1982 Dec; 35(12):2797-804. PubMed ID: 6222208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intraperitoneal penetration of ciprofloxacin.
    Lockley MR; Waldron R; Wise R; Donovan IA
    Eur J Clin Microbiol; 1986 Apr; 5(2):209-10. PubMed ID: 2941284
    [No Abstract]   [Full Text] [Related]  

  • 49. Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration.
    Campora E; Esposito M; Civalleri D; Gogioso L; Decian F; Balletto N; Falcone A; Nobile MT; Parodi B; Cafaggi S
    Anticancer Res; 1987; 7(4B):829-32. PubMed ID: 3674768
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pharmacokinetics after discontinuous intravenous administration of azlocillin].
    Naber K; Adam D
    Arzneimittelforschung; 1983; 33(3):429-32. PubMed ID: 6683518
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Temocillin revived.
    Livermore DM; Tulkens PM
    J Antimicrob Chemother; 2009 Feb; 63(2):243-5. PubMed ID: 19095679
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A study of the penetration of temocillin in the cerebrospinal fluid.
    Brückner O; Trautmann M; Borner K
    Drugs; 1985; 29 Suppl 5():162-6. PubMed ID: 4029022
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activity of human extravascular temocillin concentrations simulated in an in-vitro kinetic model against beta-lactamase producing gram-negative bacilli.
    Cooper CE; White AR; Slocombe B
    J Antimicrob Chemother; 1991 Jan; 27(1):105-15. PubMed ID: 2050587
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Temocillin in the treatment of pyelonephritis in children.
    Verboven M; Lauwers S; Pintens H
    Drugs Exp Clin Res; 1987; 13(3):171-3. PubMed ID: 3622246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Temocillin in cystic fibrosis: a retrospective pilot study.
    Kent L; Bradley JM; France M; Döring G; Carryn S; Bradbury I; Rendall J; Jones A; Elborn JS
    J Cyst Fibros; 2008 Nov; 7(6):551-4. PubMed ID: 18706868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human pharmacokinetics and antimicrobial activities of the temocillin epimers.
    Guest EA; Horton R; Mellows G; Slocombe B; Swaisland AJ; Tasker TC; White AR
    Drugs; 1985; 29 Suppl 5():154-61. PubMed ID: 4029021
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacologic data and technical feasibility of intraperitoneal doxorubicin administration.
    Demicheli R; Bonciarelli G; Jirillo A; Foroni R; Petrosino L; Targa L; Garusi G
    Tumori; 1985 Feb; 71(1):63-8. PubMed ID: 3984048
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma and peritoneal fluid concentrations of ceftriaxone after intravenous and intraperitoneal administration in horses.
    Alonso JM; Peccinini RG; Campos ML; Nitta TY; Akutagawa TYM; Crescencio AP; Alves ALG; Rodrigues CA; Watanabe MJ; Hussni CA
    Vet J; 2018 Apr; 234():72-76. PubMed ID: 29680398
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intraperitoneal Vascular Endothelial Growth Factor: A Prognostic Factor and the Potential for Intraperitoneal Bevacizumab Use in Peritoneal Surface Malignancies.
    Chia CS; Glehen O; Bakrin N; Decullier E; You B; Gilly FN; Passot G
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S880-7. PubMed ID: 26040606
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative in-vitro activity of temocillin (BRL 17421), a new penicillin.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1983 Apr; 11(4):319-24. PubMed ID: 6602123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.